InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

Current share price for ATX : $0.140 0.01 (6.67%)+

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$72 Presentation at Major Pancreatic Cancer Conference 25 Jul 2022 9:24AM $0.093 $0.140 risen by 50.54%
$72 Notice of Annual General Meeting/Proxy - YE 31 March 2022 22 Jul 2022 9:54AM $0.095 $0.140 risen by 47.37%
$72 Change of Director's Interest Notice - Dr. Chistopher Burns 7 Jul 2022 4:49PM $0.100 $0.140 risen by 40%
$72 Change of Director's Interest Notice - Dr. Robert Peach 7 Jul 2022 4:47PM $0.100 $0.140 risen by 40%
$72 Change of Director's Interest Notice - Dr. John Lambert 7 Jul 2022 4:46PM $0.100 $0.140 risen by 40%
$72 Change of Director's Interest Notice - Dr. Warwick Tong 7 Jul 2022 4:43PM $0.100 $0.140 risen by 40%
$72 Notification of cessation of securities - ATX 5 Jul 2022 2:14PM $0.096 $0.140 risen by 45.83%
$72 Application for quotation of securities - ATX 30 Jun 2022 7:15PM $0.096 $0.140 risen by 45.83%
$72 Annual General Meeting to be held Thursday 25 August 2022 29 Jun 2022 2:07PM $0.097 $0.140 risen by 44.33%
$72 Registered Office and Principal Place of Business 24 Jun 2022 1:02PM $0.095 $0.140 risen by 47.37%
$72 Notification of Expiry of Unlisted Options 9 Jun 2022 4:49PM $0.125 $0.140 risen by 12%
$72 Application for quotation of securities - ATX 9 Jun 2022 4:29PM $0.125 $0.140 risen by 12%
$72 AMP945 Shows Efficacy in Model of Lung Fibrosis 2 Jun 2022 8:17AM $0.110 $0.140 risen by 27.27%
$72 App 4G - Key to Corporate Governance Disclosures 30 May 2022 6:30PM $0.110 $0.140 risen by 27.27%
$72 2022 Corporate Governance Statement 30 May 2022 8:45AM $0.115 $0.140 risen by 21.74%
$72 Preliminary Final Report and Annual Report YE 31 March 2022 30 May 2022 8:21AM $0.115 $0.140 risen by 21.74%
$72 Amplia Receives Second Ethics Clearance for Phase 2 Trial 13 May 2022 8:40AM $0.120 $0.140 risen by 16.67%
$72 Amplia Presentation to 16th Bioshares Biotech Summit 12 May 2022 9:01AM $0.105 $0.140 risen by 33.33%
$72 AMP945 Pre-IND Meeting Outcome 9 May 2022 9:10AM $0.120 $0.140 risen by 16.67%
$72 Quarterly Activities and Cashflow Reports - March 2022 Qtr 19 Apr 2022 11:06AM $0.145 $0.140 fallen by 3.45%
$72 Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients 6 Apr 2022 11:03AM $0.140 $0.140 fallen by 0%
$72 Notification of cessation of securities - ATX 5 Apr 2022 11:34AM $0.140 $0.140 fallen by 0%
$72 AMP945 Improves Survival in Human Pancreatic Cancer Model 17 Feb 2022 8:07AM $0.165 $0.140 fallen by 15.15%
$72 ATX Abstract accepted for presentation at Cancer Conference 15 Feb 2022 1:41PM $0.160 $0.140 fallen by 12.50%
$72 Sale of Unmarketable Parcels of Shares 14 Feb 2022 12:27PM $0.170 $0.140 fallen by 17.65%

276 - 300 of 538 results

Page 12 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.